Neuronal Apoptosis Inhibitory Protein is Overexpressed in Patients with Unfavorable Prognostic Factors in Breast Cancer.
10.3346/jkms.2007.22.S.S17
- Author:
Jaewon CHOI
1
;
Yu Kyeong HWANG
;
Young Jin CHOI
;
Ki Eun YOO
;
Jeong Han KIM
;
Seok Jin NAM
;
Jung Hyun YANG
;
Sang Jin LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Young Hyuck IM
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Breast Cancer;
Neuronal Apoptosis Inhibitory rotein (NAIP);
Apoptosis;
Prognostic Factor;
Clinical Relevance
- MeSH:
Adult;
Aged;
Breast Neoplasms/*genetics/therapy;
Case-Control Studies;
Disease-Free Survival;
Female;
Gene Expression;
Humans;
Microtubule-Associated Proteins/genetics;
Middle Aged;
Neoplasm Proteins/genetics;
Neuronal Apoptosis-Inhibitory Protein/*genetics;
Prognosis;
RNA, Messenger/genetics/metabolism;
RNA, Neoplasm/genetics/metabolism;
Reverse Transcriptase Polymerase Chain Reaction;
Treatment Outcome
- From:Journal of Korean Medical Science
2007;22(Suppl):S17-S23
- CountryRepublic of Korea
- Language:English
-
Abstract:
Neuronal apoptosis inhibitory protein (NAIP) is a recently identified inhibitor of apoptosis protein. However, the clinical relevance of NAIP expression is not completely understood. In an attempt to determine the clinical relevance of NAIP expression in breast cancer, the levels of NAIP and survivin expression were measured in 117 breast cancer samples and 10 normal breast tissues using quantitative reversetranscriptase-polymerase chain reaction. While there was no evidence of NAIP expression in the normal breast tissue, NAIP was expressed in all breast cancer samples. The level of NAIP expression in breast cancer was significantly higher (257 times) than in the universal tumor control. There was a strong correlation between the level of NAIP expression and the level of survivin expression (p=0.001). The level of NAIP expression in patients with a large tumor (> or =T2) and patients with an unfavorable histology (nuclear grade III) was significantly higher than in those patients with a small tumor (T1) and patients with a favorable histology (nuclear grade I, II) (p=0.026 and p=0.050, respectively). Although the level of NAIP expression was higher in patients with other unfavorable prognostic factors, it was not significant. The three-year relapse-free survival rate was not significantly the patients showing high NAIP expression and patients showing low NAIP expression (86.47+/-4.79% vs. 78.74+/-6.57%). Further studies should include the expressions of NAIP in a larger number of patients and for a longer period of follow-up to evaluate correlation with metastasis and treatment outcome. In conclusion, NAIP is overexpressed in breast cancer patients with unfavorable clinical features such as stage and tumor size, suggesting that NAIP would play a role in the disease manifestation.
